Teva Pharmaceutical (TEVA) Tops Q1 EPS by 3c, Sales Light

Teva Pharmaceutical (NASDAQ: TEVA) reported Q1 EPS of $1.47, $0.03 better than the analyst estimate of $1.44. Revenue for the quarter rose 25% to $5.1 billion versus the consensus estimate of $5.51 billion.

For earnings history and earnings-related data on Teva Pharmaceutical (TEVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• Is Treasury selloff a major issue for stock market bulls?